Biography

Krishna Saxena joined the SGC Frankfurt July 2020. Krishna studied Biochemistry in Frankfurt (Germany) followed by a PhD (1999) in heterologous expression of membrane proteins at the Institute of Biochemistry (Frankfurt). Then, he was leading a molecular biology and protein expression group for a collaboration between Aventis Research & Technologies and the Goethe University (1999-2001), later MRPharm (2001-2002), a biotechnology company spin out of Frankfurt University and shortly part of Affinium Pharmaceuticals. The focus of his work became structure-based drug discovery by NMR spectroscopy and X-ray diffraction. From 2003-2011, he was working as a group leader (collaboration Sanofi and Goethe University) to study the family of protein kinases and subsequently to investigate biomedically relevant protein-protein interactions (PPIs) with focus on the modulation of such interactions by low molecular weight ligands guided by NMR technology. Since 2012, he has worked in the drug development platform at the DKTK German Cancer Consortium and for several industrial collaborations.